Design Therapeutics, Inc. (NASDAQ:DSGN) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. increased its stake in shares of Design Therapeutics, Inc. (NASDAQ:DSGN) by 43.0% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 257,432 shares of the company’s stock after purchasing an additional 77,472 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.45% of Design Therapeutics worth $1,385,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the stock. Palumbo Wealth Management LLC increased its position in shares of Design Therapeutics by 11.3% in the 3rd quarter. Palumbo Wealth Management LLC now owns 36,774 shares of the company’s stock valued at $198,000 after purchasing an additional 3,720 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Design Therapeutics in the 3rd quarter valued at about $66,000. Cubist Systematic Strategies LLC raised its position in shares of Design Therapeutics by 75.6% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 23,497 shares of the company’s stock worth $79,000 after acquiring an additional 10,113 shares in the last quarter. Point72 Asset Management L.P. lifted its stake in Design Therapeutics by 66.9% during the second quarter. Point72 Asset Management L.P. now owns 990,801 shares of the company’s stock worth $3,319,000 after purchasing an additional 397,285 shares during the last quarter. Finally, Almitas Capital LLC boosted its holdings in Design Therapeutics by 22.1% in the second quarter. Almitas Capital LLC now owns 1,253,248 shares of the company’s stock valued at $4,198,000 after purchasing an additional 227,180 shares in the last quarter. Hedge funds and other institutional investors own 56.64% of the company’s stock.

Design Therapeutics Stock Up 12.3 %

Shares of Design Therapeutics stock opened at $6.29 on Tuesday. The firm has a market capitalization of $356.15 million, a P/E ratio of -7.40 and a beta of 1.86. Design Therapeutics, Inc. has a 52 week low of $2.24 and a 52 week high of $7.77. The firm’s 50 day moving average is $5.80 and its two-hundred day moving average is $4.94.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.